When would I be surprised? Variability in predicted probability of survival for being "surprised" and "not surprised" to the surprise question
- PMID: 40711595
- DOI: 10.1007/s00520-025-09761-7
When would I be surprised? Variability in predicted probability of survival for being "surprised" and "not surprised" to the surprise question
Abstract
Purpose: The surprise question is commonly used in clinical practice; however, the variability in how "surprise" is defined is unclear. We examined the variability in the predicted probability of survival for being "surprised" and "not surprised" among palliative care physicians across seven timeframes.
Methods: Palliative care specialists completed the surprise question for 3 days, 1 week, 2 weeks, 1 month, 2 months, 3 months, and 6 months for patients with advanced cancer at an outpatient clinic and concurrently predicted the probability of survival (0-100%). The primary outcome, coefficient of variation (CV) for the predicted probability of survival, was computed for "surprised" and "not surprised" answers for each physician and each timeframe. A mixed-effect logistic regression assessed the probability threshold for being "surprised."
Results: Twenty physicians provided 3024 survival estimates for 216 patients (mean age 61, 50% female). When "surprised," physicians consistently predicted a probability of survival > 50%, with low variation among physicians (mean CV 6-23%) and across timeframes (mean CV 5-20%). In contrast, physicians who answered "not surprised" predicted a probability of survival from 2 to 100%, with high variation among physicians (mean CV 15-83%) and across timeframes (mean CV 22-69%). Variability increased with longer timeframes. The probability of survival thresholds for being "surprised" were ≥ 74%, ≥ 62%, ≥ 68%, ≥ 83%, and ≥ 84% for 1 week, 2 weeks, 1 month, 2 months, and 3 months, respectively.
Conclusion: We found low variability for predicted probability of survival when clinicians were "surprised" but high variability when they were "not surprised."
Keywords: Clinical decision-making; Forecasting; Neoplasms; Palliative care; Prognosis.
© 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Declarations. Ethics approval: This study was performed in line with the principles of the Declaration of Helsinki and all procedures were in accordance with the ethical standards of the institutional and/or national research committees. Protocol approval (2017–0942) was obtained from the University of Texas MD Anderson Cancer Center Institutional Review Board. Consent to participate: Written informed consent was obtained from all individual participants included in the study. Competing interests: The authors declare no competing interests.
Similar articles
-
Prescription of Controlled Substances: Benefits and Risks.2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30726003 Free Books & Documents.
-
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23. Clin Orthop Relat Res. 2024. PMID: 39051924
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
-
Performance of the Palliative Prognostic Index for cancer patients: A systematic review and meta-analysis.Palliat Med. 2023 Sep;37(8):1144-1167. doi: 10.1177/02692163231180657. Epub 2023 Jun 13. Palliat Med. 2023. PMID: 37310019
-
Are Current Survival Prediction Tools Useful When Treating Subsequent Skeletal-related Events From Bone Metastases?Clin Orthop Relat Res. 2024 Sep 1;482(9):1710-1721. doi: 10.1097/CORR.0000000000003030. Epub 2024 Mar 22. Clin Orthop Relat Res. 2024. PMID: 38517402
References
-
- Abdi H (2010) Coefficient of variation. Encyclop Res Des 1:169–171
-
- Anderson F, Downing GM, Hill J, Casorso L, Lerch N (1996) Palliative performance scale (PPS): a new tool. J Palliat Care 12:5–11 - PubMed
-
- Anzai T, Sato T, Fukumoto Y, Izumi C, Kizawa Y, Koga M, Nishimura K, Ohishi M, Sakashita A, Sakata Y, Shiga T, Takeishi Y, Yasuda S, Yamamoto K, Abe T, Akaho R, Hamatani Y, Hosoda H, Ishimori N, Kato M, Kinugasa Y, Kubozono T, Nagai T, Oishi S, Okada K, Shibata T, Suzuki A, Suzuki T, Takagi M, Takada Y, Tsuruga K, Yoshihisa A, Yumino D, Fukuda K, Kihara Y, Saito Y, Sawa Y, Tsutsui H, Kimura T (2021) JCS/JHFS 2021 statement on palliative care in cardiovascular diseases. Circ J 85:695–757. https://doi.org/10.1253/circj.CJ-20-1127 - DOI - PubMed
-
- Aronhime S, Calcagno C, Jajamovich GH, Dyvorne HA, Robson P, Dieterich D, Fiel MI, Martel-Laferriere V, Chatterji M, Rusinek H, Taouli B (2014) DCE-MRI of the liver: effect of linear and nonlinear conversions on hepatic perfusion quantification and reproducibility. J Magn Reson Imaging 40:90–98. https://doi.org/10.1002/jmri.24341 - DOI - PubMed
-
- Chu C, Engels Y, Suh SY, Kim SH, White N (2023) Should the surprise question be used as a prognostic tool for people with life-limiting illnesses? J Pain Symptom Manage 66:e437–e441. https://doi.org/10.1016/j.jpainsymman.2023.05.003 - DOI - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical